GT719 Injection for Recurrent/Refractory Antibody Mediated Systemic Immune Diseases

Launched by GRIT BIOTECHNOLOGY · Jun 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called GT719 Injection for adults with certain neurological disorders that are caused by the immune system attacking the body. This study is exploring how safe the treatment is, how it affects the cells in the body, and if it can help improve the patients' conditions. The trial is currently looking for participants aged 18 to 70 who have been diagnosed with these recurring or hard-to-treat conditions and meet specific criteria, such as being able to commit to the study and having expected survival for at least 12 weeks.

Participants in this study will receive the GT719 treatment and will be monitored closely for safety and effectiveness. It is important to know that individuals who have had certain medical procedures, like organ transplants or recent blood clots, may not be eligible. Additionally, those who have taken corticosteroid medications recently may also be excluded. If you or someone you know is interested in participating, this trial could offer a chance to explore a new treatment option for challenging neurological disorders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
• • Expected survival period\>12 weeks.
• • Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment.
• Exclusion Criteria:
• • History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation.
• • History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.
• • Received systemic corticosteroids within 7 days prior to GT719 infusion, except for inhaled corticosteroids